Austria’s Miracor Medical Systems is boosting its presence in the U.K. with a new sales office and 2 clinical trials of its heart attack-treatment device.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
TAVI: FDA adds ‘valve-in-valve’ indication for Medtronic’s CoreValve
TAVI: Japan approves Medtronic’s CoreValve
Boston Scientific touts 1st Watchman implantations
Volcano wins CE Mark for new FFR software
Cardiovascular imaging company Volcano nailed down a CE Mark in the European Union for diagnostic software that helps assess serial lesions and diffuse coronary disease in a simpler way.
Study: Uncommon form of heart attack likely runs in family
Svelte Medical adds $16m for wrist-delivered stent
Svelte Medical Systems today said it plans to use the $16 million it just raised to commercialize its wrist-delivered stenting technology.
New Providence, N.J.-based Svelte said the round involved current investors and was led by CNF Investments, the West Health Investment Fund and New Science Ventures.
ACC 2015 Roundup: CTA no benefit, Abbott’s MitraClip, Philips’ IntelliSpace
ACC 2015: Danish study finds TAVI safe for low-risk patients
ACC 2015: Medtronic readies ‘drug-filled stent’ trial
UPDATE: Boston Scientific jumps on Watchman approval
Investors sent shares of Boston Scientific (NYSE:BSX) up nearly 4% today after the medical device company said the FDA approved its long-delayed Watchman anti-stroke device.